ClinicalTrials.gg
CompletedNCT06557902Updated Jul 24, 2026

Safety, Tolerability and Pharmacokinetics of Lumateperone in Pediatric Patients With Autism Spectrum Disorder

A Phase 1 interventional study of Lumateperone 10.5 mg capsule and Lumateperone 21 mg capsule in Autism Spectrum Disorder, sponsored by Intra-Cellular Therapies, Inc.. Completed at 7 sites in United States. Open to participants aged 5 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by Intra-Cellular Therapies, Inc. (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled May 2024, registered Aug 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
5 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 773 studies in Autism Spectrum Disorder with a site in United States — 165 open to participants now, 204 under way, 9 of them phase 3. Autism Spectrum Disorder · United States.

Enrollment
418th of 658
33 · median 50
Started
2024
with 54 others
Phase 1
44 of 773
8 open now
Registered
681st of 773
by date

Among the 773 studies in Autism Spectrum Disorder with a site in United States, this one is the 418th largest by enrollment of the 658 interventional ones that give a count, is one of 55 that started in 2024, is one of 44 in phase 1, and was the 681st registered.

Autism Spectrum Disorder

1,728 studies on the registry are indexed under Autism Spectrum Disorder; 500 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

165 of the 773 studies in Autism Spectrum Disorder with a site in United States are open now. Recruiting first, the newest first:

160 more — sign in →

All 165 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 349 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 294 (84%) stop at 75 or younger; 298 take children under 18; 92 take healthy volunteers.

This study: 5 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 773 studies in Autism Spectrum Disorder with a site in United States, or all of them as a file.
02

Study summary

Study ITI-007-035 is a Phase 1b, multicenter, open-label study to evaluate the safety, tolerability, and PK of lumateperone for pediatric patients with Autism Spectrum Disorder.

03

Conditions studied

  • Autism Spectrum Disorder
04

Who can participate

Ages eligible
5 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients between 5 to less than 13 years of age
  • Primary clinical diagnosis of ASD with symptoms of irritability
  • ABC-I subscale score of ≥12 at Screening
  • CGI-S score of ≥3 at Screening
  • (BMI) greater than the 5th percentile according to age- and gender-specific CDC Clinical Growth Charts (2000) at Screening
  • Ability to swallow capsules

Exclusion criteria

Exclusion Criteria:

  • Has a primary psychiatric diagnosis other than ASD
  • Reports suicidal ideation (Type 3, 4 or 5 on the Baseline/Screening version of the C-SSRS) within 6 months prior to Screening, or any suicidal behavior within 2 years prior to Screening, and/or the Investigator assesses the patient to be a safety risk to him/herself or others
  • abnormality within 2 years of Screening that in the Investigator's opinion may place the patient at risk or interfere with study outcome variables
  • History of a clinically significant cardiac disorder and/or abnormal screening or a corrected for heart rate using Fridericia formula (QTcF) > 460 msec at Screening
  • Patients with a history of orthostatic hypotension or who have orthostatic hypotension at Screening
  • Has a history of uncontrolled/disruptive behavior in the past 30 days that, in the Investigator's opinion, would preclude the ability to participate in study procedures
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Group 1 (10 to less than 13 years)

    Lumateperone capsule once daily: 10.5 mg on Days 1 and 2; 10.5 mg or 21 mg on Day 3; 10.5 mg or 21 mg on Days 4 and 5

    Drug: Lumateperone 10.5 mg capsule · Drug: Lumateperone 21 mg capsule

  • Experimental
    Group 2 (5 to less than 10 years)

    Lumateperone ODT once daily: 5 mg on Days 1 and 2; 5 mg or 10.5 mg on Day 3; 5 mg or 10.5 mg on Days 4 and 5; dosing regimen may be adjusted after the first 6 patients dosed and will not exceed 21 mg in subsequent patients

    Drug: Lumateperone 5 mg ODT · Drug: Lumateperone 10.5 mg ODT · Drug: Lumateperone 15.5 mg ODT · Drug: Lumateperone 21 mg ODT

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics: Cmax

    Maximum plasma concentration of lumateperone

    Time frame: Day 5

  2. Pharmacokinetics: Tmax

    Time of maximum plasma concentration of lumateperone

    Time frame: Day 5

  3. Pharmacokinetics: AUC0-tau

    Area under the plasma lumateperone concentration time curve from time zero to the end of dosing (tau)

    Time frame: Day 5

Secondary outcomes

  1. Percentage of patients with treatment-emergent adverse events

    Time frame: Up to 30 days after last dose

  2. Change from baseline in systolic and diastolic blood presssure

    Time frame: Day 6

  3. Change from baseline in ECG QT interval

    Time frame: Day 6

  4. Change from baseline in hemoglobin

    Time frame: Day 6

  5. Change from baseline in white blood cell count

    Time frame: Day 6

  6. Change from baseline in aspartate aminotransferase

    Time frame: Day 6

  7. Change from baseline in alanine aminotransferase

    Time frame: Day 6

  8. Change from baseline in Abnormal Involuntary Movement Scale (AIMS)

    AIMS is a measure of facial and oral movements, extremity movements and trunk movements. Items are rated on a scale from none (0) to severe (4).

    Time frame: Day 6

07

Study locations

7 sites
  • APG Research LLC
    Orlando, Florida 32803, United States
  • CenExeli Research LLC
    Atlanta, Georgia 30030, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • CenExeli Research LLC 1
    Savannah, Georgia 31405, United States
  • Midwest Research Group
    Saint Charles, Missouri 63304, United States
  • Alivation Research LLC
    Lincoln, Nebraska 68526, United States
  • Core Clinical Research
    Everett, Washington 98201, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Nov 2025, 18 months.

Of 35 phase 1 interventional studies under Autism Spectrum Disorder, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 27. This study's 18 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2024
First posted
Aug 16, 2024
StartActual
May 10, 2024
Primary completionActual
Nov 26, 2025
CompletionActual
Nov 26, 2025
Last update
Jul 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06557902
Responsible party
Sponsor
First posted
Aug 16, 2024
Start date
May 10, 2024
Primary completion
Nov 26, 2025
Completion
Nov 26, 2025
Last update
Jul 24, 2026

Study contacts

Intra-Cellular Therapies, Inc. Clinical Trial
study director · Intra-Cellular Therapies, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lumateperone

Start the discussion